Joseph Gut - thasso
Posted in Allelic Variant, Genetic Background, Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine
No Comments ↓
January 13, 2019 – Are genetic variations in the sweet taste receptor gene related to chocolate powder and dietary fiber intake in obese children and adolescents? This was the question in a recent study just published in the Journal of Personalized Medicine. On one hand,
…
Joseph Gut - thasso
Posted in Allelic Variant, Genetic Background, New Research, Pediatrics, Thasso Post, Theragenomic Medicine
No Comments ↓
…
Joseph Gut - thasso
Posted in Allelic Variant, Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine
No Comments ↓
March 26, 2017 – There is ample evidence that the burden of obesity is not the same across ethnic groups. While diet and lifestyle play a large role in determining body weight, there is also a heritable component. Unfortunately,  most prior studies that have evaluated the role of genes in obesity have looked mostly at people of European or Asian descent,
…
Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF
Posted in PubMed Entry, Thasso Post, Theragenomic Medicine
1 Comment ↓
Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF
JAMA Dermatol 2016 Apr;
PMID: 27120802
Abstract
Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear.
…
December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as hypertension,
…
September 13, 2014 – The U.S. Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension),
…
Optional: Social Subscribe/Login
thasso: recent comments